1 Margolis SS,Sell GL,Zbinden MA,et al.Angelman Syndrome.Neurotherapeutics,2015,12:641-650. 2 Buiting K,Clayton-Smith J,Driscoll DJ,et al.Clinical utility gene card for:Angelman Syndrome.Eur J Hum Genet,2015,23.doi.10.1038\ejhg.2014.93. 3 Williams CA,Beaudet AL,Clayton-Smith J,et al.Angelman syndrome 2005:updated consensus for diagnostic criteria.Am J Med Genet A,2006,140:413-418. 4 Martinez-Noel G,Luck K,Kuhnle S,et al.Network Analysis of UBE3A/E6AP-Associated Proteins Provides Connections to Several Distinct Cellular Processes.J Mol Biol,2018,430:1024-1050. 5 Ramirez J,Lectez B,Osinalde N,et al.Quantitative proteomics reveals neuronal ubiquitination of Rngo/Ddi1 and several proteasomal subunits by Ube3a,accounting for the complexity of Angelman syndrome.Hum Mol Genet,2018,27:1955-1971. 6 Tomaic V,Banks L.Angelman syndrome-associated ubiquitin ligase UBE3A/E6AP mutants interfere with the proteolytic activity of the proteasome.Cell Death Dis,2015,6:1625. 7 Stockwell J,Chen Z,Niazi M,et al.Protein phosphatase role in adenosine A1 receptor-induced AMPA receptor trafficking and rat hippocampal neuronal damage in hypoxia/reperfusion injury.Neuropharmacology,2016,102:254-265. 8 Wang J,Lou SS,Wang T,et al.UBE3A-mediated PTPA ubiquitination and degradation regulate PP2A activity and dendritic spine morphology.Proc Natl Acad Sci USA,2019,116:12500-12505. 9 Sage-Schwaede A,Engelstad K,Salazar R,et al.Exploring mTOR inhibition as treatment for mitochondrial disease.Ann Clin Transl Neurol,2019,6:1877-1881. 10 Sawicka K,Zukin RS.Dysregulation of mTOR signaling in neuropsychiatric disorders:therapeutic implications.Neuropsychopharmacology,2012,37:305-306. 11 Sun J,LiuY,Tran J,et al.mTORC1-S6K1 inhibition or mTORC2 activation improves hippocampal synaptic plasticity and learning in Angelman syndrome mice.Cell Mol Life Sci,2016,73:4303-4314. 12 Sun J,Liu Y,Moreno S,et al.Imbalanced mechanistic target of rapamycin C1 and C2 activity in the cerebellum of Angelman syndrome mice impairs motor function.J Neurosci,2015,35:4706-4718. 13 Thomanetz V,Angliker N,Cloetta D,et al.Ablation of the mTORC2 component rictor in brain or Purkinje cells affects size and neuron morphology.J Cell Biol,2013,201:293-308. 14 Im HI,Kenny PJ.MicroRNAs in neuronal function and dysfunction.Trends Neurosci,2012,35:325-334. 15 Vatsa N,Kumar V,Singh BK,et al.Down-Regulation of miRNA-708 Promotes Aberrant Calcium Signaling by Targeting Neuronatin in a Mouse Model of Angelman Syndrome.Front Mol Neurosci,2019,12:35. 16 Frohlich J,Miller MT,Bird LM,et al.Electrophysiological Phenotype in Angelman Syndrome Differs Between Genotypes.Biol Psychiatry,2019,85:752-759. 17 Shaaya EA,Grocott OR,Laing O,et al.Seizure treatment in Angelman syndrome:A case series from the Angelman Syndrome Clinic at Massachusetts General Hospital.Epilepsy Behav,2016,60:138-141. 18 Evangeliou A,Doulioglou V,Haidopoulou K,et al.Ketogenic diet in a patient with Angelman syndrome.Pediatr Int,2010,52:831-834. 19 Grocott OR,Herrington KS,Pfeifer HH,et al.Low glycemic index treatment for seizure control in Angelman syndrome:A case series from the Center for Dietary Therapy of Epilepsy at the Massachusetts General Hospital.Epilepsy Behav,2017,68:45-50. 20 Spruyt K,Braam W,Curfs LM.Sleep in Angelman syndrome:A review of evidence.Sleep Med Rev,2018,37:69-84. 21 Huang HS,Allen JA,Mabb A M,et al.Topoisomerase inhibitors unsilence the dormant allele of Ube3a in neurons.Nature,2011,481:185-189. 22 Gu B,Carstens KE,Judson MC,et al.Ube3a reinstatement mitigates epileptogenesis in Angelman syndrome model mice.J Clin Invest,2019,129:163-168. 23 Silva-Santos S,van Woerden GM,Bruinsma CF,et al.Ube3a reinstatement identifies distinct developmental windows in a murine Angelman syndrome model.J Clin Invest,2015,125:2069-2076. 24 Guzzetti S,Calzari L,Buccarello L,et al.Taurine Administration Recovers Motor and Learning Deficits in an Angelman Syndrome Mouse Model.Int J Mol Sci,2018,19:1088. 25 Grieco JC,Ciarlone SL,Gieron-Korthals M,et al.An open-label pilot trial of minocycline in children as a treatment for Angelman syndrome.BMC Neurol,2014,14:232. 26 Sonzogni M,Wallaard I,Santos SS,et al.A behavioral test battery for mouse models of Angelman syndrome:a powerful tool for testing drugs and novel Ube3a mutants.Mol Autism,2018,9:47